Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date An
Replimune Group, Inc. (NASDAQ: REPL ), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderpare